Trials / Unknown
UnknownNCT04910854
Surufatinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
A Study of Surufatinib in the Treatment of Recurrent/Metastatic Adenocarcinomas of the Head and Neck
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase II, open label study of Surufatinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib | Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), The curative effect was evaluated every 8 weeks. |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2022-03-31
- Completion
- 2023-12-31
- First posted
- 2021-06-02
- Last updated
- 2021-06-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04910854. Inclusion in this directory is not an endorsement.